Skip to main content

Advertisement

SpringerLink
Log in

Seminal plasma protein in renal cell carcinoma: expression of semenogelin I is a predictor for cancer progression and prognosis

  • Research Article
  • Published:
Tumor Biology

Abstract

The incidence of renal cell carcinoma (RCC) has been steadily rising each year. There are currently few recognized biomarkers for the diagnosis and prognosis of RCC. We investigated semenogelin I (Sg I) expression and its clinical significance in patients with RCC. The expression levels of Sg I and its protein were measured by qPCR and Western blotting, respectively. Immunohistochemistry was used to investigate the protein expression of Sg I in RCC and normal renal tissue from 53 patients. The Kaplan–Meier method and log-rank test were used to evaluate the data. By qRCR (p < 0.01) and Western blot, the level of Sg I expression in benign tissues was higher than that in RCC tissues. Expression of Sg I was observed in 30 (57 %) RCC cases, which was significantly lower than that observed in benign renal tissues from the same patients [Sg I positive in 53 (100 %) cases (p < 0.0001)] by immunohistochemistry. There was an inverse relation between Sg I expression and clinical stage (pT1-2 vs pT3-4, p < 0.0001). Patients with Sg I-negative tumor had a significantly higher risk of recurrence (Kaplan–Meier and log-rank tests, p < 0.0001). There was low Sg I expression in RCC. Sg I expression has potential value in predicting cancer progression and prognosis. These findings support the use of Sg I as a novel biomarker for RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Li Z, Zhang Y, Kim WJ, et al. PGE2 promotes renal carcinoma cell invasion through activated RalA. Oncogene. 2013;32:1408.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Sun M, Lughezzani G, Perrotte P, et al. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010;7:327.

    Article  CAS  PubMed  Google Scholar 

  3. Negrier S. Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices. Oncology. 2012;82:189.

    Article  PubMed  Google Scholar 

  4. Cairns P. Renal cell carcinoma. Cancer Biomark. 2010;9:461.

    PubMed  Google Scholar 

  5. Canacci AM, Izumi K, Zheng Y, et al. Expression of semenogelins I and II and its prognostic significance in human prostate cancer. Prostate. 2011;71:1108.

    Article  CAS  PubMed  Google Scholar 

  6. Wang Z, Widgren EE, Sivashanmugam P, et al. Association of eppin with semenogelin on human spermatozoa. Biol Reprod. 2005;72:1064.

    Article  CAS  PubMed  Google Scholar 

  7. Jonsson M, Linse S, Frohm B, et al. Semenogelins I and II bind zinc and regulate the activity of prostate-specific antigen. Biochem J. 2005;387:447.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Mitra A, Richardson RT, O’Rand MG. Analysis of recombinant human semenogelin as an inhibitor of human sperm motility. Biol Reprod. 2010;82:489.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Jonsson M, Lundwall A, Malm J. The semenogelins: proteins with functions beyond reproduction? Cell Mol Life Sci. 2006;63:2886.

    Article  CAS  PubMed  Google Scholar 

  10. Lundwal A, Bjartell A, Olsson AY, Malm J. Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. Mol Hum Reprod. 2002;8:805.

    Article  Google Scholar 

  11. Bonilha VL, Rayborn ME, Shadrach K, et al. Characterization of semenogelin proteins in the human retina. Exp Eye Res. 2006;83:120.

    Article  CAS  PubMed  Google Scholar 

  12. Rodrigues RG. Semenogelins are ectopically expressed in small cell lung carcinoma. Clin Cancer Res. 2001;7:854.

    CAS  PubMed  Google Scholar 

  13. Zhang Y, Wang Z, Liu H, et al. Pattern of gene expression and immune responses to semenogelin 1 in chronic hematologic malignancies. J Immunother. 2003;26:461.

    Article  CAS  PubMed  Google Scholar 

  14. Wang Z-J, Zhang W, Feng N-H, et al. Molecular mechanism of epididymal protease inhibitor modulating the liquefaction of human semen. Asian J Androl. 2008;10:770.

    Article  PubMed  Google Scholar 

  15. Izumi K, Li Y, Zheng Y, et al. Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy. Hum Pathol. 2012;43:1991.

    Article  CAS  PubMed  Google Scholar 

  16. Roan, N. R., Liu, H., Usmani, S. M. et al.: Liquefaction of semen generates and later degrades a conserved semenogelin peptide that enhances HIV infection. J Virol. 2014;88(13):7221–7234.

  17. Malm J, Hellman J, Magnusson H, et al. Isolation and characterization of the major gel proteins in human semen, semenogelin I and semenogelin II. Eur J Biochem. 1996;238:48.

    Article  CAS  PubMed  Google Scholar 

  18. Silva EJ, Hamil KG, O’Rand MG. Interacting proteins on human spermatozoa: adaptive evolution of the binding of semenogelin I to EPPIN. PLoS One. 2013;8:e82014.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Chawla SN, Crispen PL, Hanlon AL, et al. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175:425.

    Article  PubMed  Google Scholar 

  20. Ambring A, Bjorholt I, Lesen E, et al. Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study. Med Oncol. 2013;30:331.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Coral S, Sigalotti L, Altomonte M, et al. 5-Aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res. 2002;8:2690.

    CAS  PubMed  Google Scholar 

  22. Zhang Y, Wang Z, Zhang J, et al. Core promoter sequence of SEMG I spans between the two putative GATA-1 binding domains and is responsive to IL-4 and IL-6 in myeloma cells. Leuk Res. 2009;33:166.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the National Natural Science Foundation of China (No. 81270685).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. State key Laboratory of Reproductive Medicine and Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Guangzhou Road 300#, Nanjing, 210029, People’s Republic of China

    Shengli Zhang, Jianzheng Fang, Chao Qin, Shifeng Su, Yunfei Deng, Zhen Song, Yi Zhang, Hainan Wang, Changjun Yin & Zengjun Wang

  2. Jiangsu Province Official Hospital, Nanjing, China

    Xiangxiang Zhang

Authors
  1. Shengli Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianzheng Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiangxiang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chao Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shifeng Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yunfei Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhen Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hainan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Changjun Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Zengjun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zengjun Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, S., Fang, J., Zhang, X. et al. Seminal plasma protein in renal cell carcinoma: expression of semenogelin I is a predictor for cancer progression and prognosis. Tumor Biol. 35, 9095–9100 (2014). https://doi.org/10.1007/s13277-014-2184-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2184-6

Keywords

Search

Navigation